Your browser is no longer supported. Please, upgrade your browser.
Settings
CGIX [NASD]
Cancer Genetics, Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own7.49% Shs Outstand10.56M Perf Week19.72%
Market Cap61.31M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.51M Perf Month47.25%
Income-4.10M PEG- EPS next Q- Inst Own5.40% Short Float32.74% Perf Quarter141.39%
Sales6.30M P/S9.73 EPS this Y22.70% Inst Trans99.24% Short Ratio0.49 Perf Half Y-2.64%
Book/sh2.06 P/B2.86 EPS next Y- ROA-35.70% Target Price- Perf Year40.57%
Cash/sh0.11 P/C55.74 EPS next 5Y40.00% ROE-76.50% 52W Range1.92 - 17.50 Perf YTD112.64%
Dividend- P/FCF- EPS past 5Y41.70% ROI-59.00% 52W High-66.34% Beta2.74
Dividend %- Quick Ratio0.60 Sales past 5Y-6.50% Gross Margin45.70% 52W Low206.77% ATR1.10
Employees110 Current Ratio0.60 Sales Q/Q-23.80% Oper. Margin-69.70% RSI (14)53.44 Volatility18.07% 19.11%
OptionableNo Debt/Eq0.04 EPS Q/Q75.50% Profit Margin-71.50% Rel Volume0.21 Prev Close6.23
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume2.33M Price5.89
Recom3.00 SMA204.07% SMA5038.54% SMA20063.95% Volume478,942 Change-5.46%
Dec-07-17Initiated Maxim Group Buy $6
Jun-27-17Initiated Dawson James Buy
Jun-26-17Initiated The Benchmark Company Speculative Buy $6
Sep-26-16Initiated Rodman & Renshaw Buy $6
Feb-16-21 04:45PM  
Feb-11-21 07:26AM  
Feb-10-21 11:00PM  
Feb-06-21 11:52AM  
Feb-05-21 09:00PM  
Feb-04-21 03:45AM  
Feb-03-21 06:00PM  
Feb-01-21 05:16PM  
Jan-30-21 07:06PM  
Jan-28-21 06:15PM  
04:02PM  
Jan-16-21 02:54PM  
Jan-14-21 05:27PM  
Jan-09-21 10:29AM  
Jan-07-21 04:06PM  
04:05PM  
Dec-19-20 04:17PM  
Dec-18-20 10:28PM  
Dec-08-20 12:12PM  
Dec-07-20 04:54PM  
Dec-01-20 07:14PM  
Nov-30-20 08:50PM  
Nov-18-20 08:00AM  
Nov-17-20 12:10PM  
Nov-13-20 10:37PM  
Nov-12-20 05:31PM  
04:25PM  
12:25PM  
Nov-02-20 04:00PM  
Oct-28-20 09:55PM  
05:54PM  
Oct-20-20 12:30PM  
Oct-19-20 03:24PM  
Oct-14-20 07:00PM  
01:14PM  
Oct-13-20 08:20PM  
Oct-09-20 08:01AM  
Oct-05-20 05:55PM  
Oct-02-20 08:01PM  
Sep-26-20 03:01AM  
Sep-25-20 04:55PM  
Sep-24-20 03:55PM  
10:48AM  
Sep-23-20 11:45PM  
03:00PM  
Sep-17-20 02:50PM  
Sep-16-20 01:24PM  
Sep-12-20 11:00AM  
Sep-10-20 08:50PM  
08:00AM  
Sep-03-20 08:00AM  
01:10AM  
Sep-02-20 08:00PM  
Sep-01-20 10:30PM  
07:17PM  
Aug-31-20 11:36AM  
Aug-27-20 04:35PM  
12:45PM  
10:59AM  
Aug-26-20 06:39PM  
06:09PM  
Aug-25-20 06:10PM  
03:00PM  
10:21AM  
08:38AM  
06:20AM  
Aug-24-20 05:58PM  
03:41PM  
08:00AM  
Aug-14-20 07:30AM  
Jun-24-20 05:30PM  
Jun-01-20 08:00AM  
May-12-20 06:37AM  
Feb-20-20 09:00AM  
Nov-20-19 08:00AM  
Nov-14-19 05:29AM  
Oct-24-19 04:15PM  
08:30AM  
Oct-17-19 06:55AM  
Aug-20-19 08:00AM  
Jul-16-19 12:44PM  
08:44AM  
Jul-15-19 04:22PM  
04:10PM  
Jun-25-19 07:24AM  
Jun-24-19 07:00AM  
Jun-05-19 02:00AM  
May-20-19 05:06PM  
05:00PM  
Apr-16-19 07:22AM  
07:00AM  
Mar-26-19 08:06AM  
Feb-14-19 07:04AM  
Jan-31-19 04:01PM  
Jan-29-19 07:25AM  
Jan-28-19 10:33PM  
04:00PM  
Jan-21-19 09:21AM  
Jan-16-19 08:45AM  
Jan-14-19 05:29PM  
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.